Sildenafil (for pulmonary arterial hypertension)

Product:
SILDENAFIL (Revatio®) 20mg tablet

Class of drugs:
Phosphodiesterase inhibitor

Indication:
Treatment of pulmonary arterial hypertension

Manufacturer:
Pfizer Canada Inc.

Highlights of Recommendation:
- Sildenafil (Revatio) is used to treat pulmonary arterial hypertension, a disease marked by an increase in blood pressure in the artery which takes blood from the heart to the lungs.
- In a key study that the Committee reviewed, sildenafil (Revatio) improved the patients' performance in the 6-minute walk test when compared to patients taking a placebo. In this trial, the quality of life of patients who used sildenafil (Revatio) also improved.
- There are no long-term published studies for sildenafil (Revatio) in the treatment of pulmonary arterial hypertension; therefore, the long-term effectiveness of the drug is unknown. There is no evidence that sildenafil decreases mortality.
- Overall, the Committee acknowledged that sildenafil (Revatio) appears to have short-term benefits in improving patients' exercise capacity and their quality of life. However, evidence on long-term benefit and safety is lacking. The Committee concluded that sildenafil (Revatio) may be cost-effective in selected patients with pulmonary arterial hypertension. It was recommended sildenafil (Revatio) be funded through the EAP for the treatment of pulmonary arterial hypertension with specific criteria.

Background:
Pulmonary arterial hypertension occurs when dangerously high blood pressure builds up in the blood vessels that lead from the heart to the lungs. The small blood vessels in the lungs narrow and their walls thicken, causing the pressure to build and back up. The heart is unable to keep up with the extra work needed to pump blood through the lungs, resulting in right-sided heart failure.

Patients with pulmonary arterial hypertension experience fatigue, dizziness, shortness of breath, chest pain and, eventually, heart failure and death.

The disease can occur on its own due to unknown causes, or as a complication of congenital heart disease, HIV or connective tissue diseases such as scleroderma.

Sildenafil (Revatio) works by blocking an enzyme called phosphodiesterase type 5, relaxing the pulmonary blood vessels, and improving blood flow.

CED Recommendation
The CED recommended that sildenafil (Revatio) be funded through the Exceptional Access Program (EAP), according to specific criteria, on the basis that the drug has demonstrated short-term clinical benefits and value for money in selected patients with pulmonary arterial hypertension.

Executive Officer Decision
Based on the CED’s recommendation, the Executive Officer decided to fund sildenafil (Revatio) through the EAP for the treatment of pulmonary arterial hypertension, according to specific criteria.

Status
Funding available through the Ontario Public Drug Programs via the EAP.

continued…
Detailed Discussion:

* The Committee reviewed one published randomized controlled trial of 12 weeks duration in 278 patients with pulmonary arterial hypertension (Galie et al., NEJM 2005). Compared to placebo, sildenafil (Revatio) 20mg three times daily was associated with statistically significant improvements in the six-minute walk test (mean difference of 45 meters vs. placebo), the percentage of patients with an improvement of at least one World Health Organization (WHO) functional class (28 percent for sildenafil vs. seven percent for placebo), and measures of quality of life.

* The clinical trial design and duration did not allow for the evaluation of time to death or time to transplantation. Because only short-term studies are available, the long-term safety and effectiveness of sildenafil (Revatio) in the treatment of pulmonary arterial hypertension is unknown.

* No significant dose response effect was observed for the three doses (20mg, 40mg, 80mg three times daily) of sildenafil (Revatio).

* The pivotal study did not show any statistically significant difference in the incidence of serious adverse events between sildenafil (Revatio) and placebo. Sildenafil (Revatio) use was associated with higher rates of nose bleeds and eye disorders.

* The Committee evaluated the cost-effectiveness of sildenafil (Revatio) in patients with WHO class II and WHO class III pulmonary arterial hypertension. Value for money was not demonstrated in patients with WHO class II pulmonary arterial hypertension. In WHO class III patients, sildenafil (Revatio) appeared to provide reasonable cost-effectiveness.

* There are no direct head-to-head studies between sildenafil (Revatio) and bosentan to determine comparative efficacy and safety between the two agents. Sildenafil (Revatio) costs approximately $30 per day (at the 20mg three times daily dose), while bosentan costs approximately $130 per day (at a dose of 125mg twice daily). In the absence of evidence indicating one agent is clinically superior to another, the Committee felt that sildenafil (Revatio) is a cost-effective alternative to bosentan in patients with WHO class III pulmonary arterial hypertension of either primary origin or secondary to connective tissue disease.

* The Committee expressed concerns with combination use of sildenafil (Revatio) with other pulmonary arterial hypertension agents (e.g. bosentan). Currently, there are no high quality randomized controlled trials to support the use of combination therapy.

* Overall, the Committee acknowledged sildenafil (Revatio) appears to have short-term benefits in improving pulmonary hemodynamics and increasing the six-minute walk distance in the relevant population. However, the supporting evidence stems from one randomized clinical trial of 12 weeks. The long-term effectiveness of this drug in patients with pulmonary arterial hypertension is unknown. Key outcomes such as time to death or transplantation have not been evaluated. Nevertheless, the Committee recognized this therapy offers short-term clinical benefit and value for money in patients with WHO Class III pulmonary arterial hypertension.

* The CED recommended that sildenafil (Revatio) 20mg tablets be funded through the Exceptional Access Program (EAP), according to the following criteria:

  - For patients with WHO class III pulmonary arterial hypertension of either primary origin or secondary to connective tissue disease.

  - Patients must have received an adequate trial of pulmonary vasodilators, and warfarin, with persistent, disabling symptoms and signs.

  - Patient is followed by a specialist in pulmonary arterial hypertension.

  - The approved dose of sildenafil (Revatio) should be limited to 20mg three times daily.

  - Consideration will not be given for combinations with any of the following drug therapies: bosentan, epoprostenol, treprostinil.

CEDAC Recommendation:

(http://www.cadth.ca/index.php/en/cdr/recommendations)

The Canadian Expert Drug Advisory Committee (CEDAC) recommended that sildenafil (Revatio) be listed in the same manner that drug plans list bosentan.